Skip to content
TerminatedPhase 2

Phase 2 Clinical Trial of GH001 in Bipolar II Disorder

NCT05839509 · GH Research Ireland Limited

Closed to entry
Status
Not accepting participants
Phase 2
Phase
6
Target enrolment
7
Study sites
Outside the US

What it is testing

Summary

This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 participants with clinically diagnosed bipolar disorder (BD) type II and experiencing a current episode of depression will be included in this study. The participants will receive an individualized dosing regimen (IDR) with at least one and up to three doses of GH001 administered within a single day.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • The anti-depressive effects of GH001 evaluated by the change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) assessed at Day 7

    Measured over From Baseline to Day 7

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 64 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Is male or female and in the age range between 18 and 64 years (inclusive) at screening * Has a body mass index (BMI) in the range of 18.5 and 35 kg/m2 (inclusive) at screening * Meets the trial criteria for bipolar II disorder and is experiencing a major depressive episode, as assessed by a trial psychiatrist or registered clinical psychologist Exclusion Criteria: * Has bipolar II disorder with rapid cycling (four or more episodes of hypomania or depressive episodes in previous 12-month period) * Has, based on history, psychiatric assessment, and evaluation of the MINI, a current or prior diagnosis of bipolar I disorder, a manic episode, a psychotic disorder, MDD or other mood disorder with psychotic features, obsessive compulsive disorder, PTSD, autism spectrum disorder, borderline personality disorder, schizophrenia, delusional disorder, paranoid personality disorder, schizoaffective disorder, clinically significant intellectual disability, or any other psychiatric comorbidity that renders the patient unsuitable for the trial according to the investigator's judgment * Has one or more first degree relatives with a current or previously diagnosed psychotic disorder, bipolar I disorder or MDD with psychotic features * Has taken prohibited medication or prohibited dietary supplements within the specified timeframe prior to dosing * Has previously experienced a significant adverse reaction to a hallucinogenic or psychedelic drug according to the investigator's judgment * Has a clinically significant abnormality in physical examination, vital signs, ECG, or clinical laboratory parameters which renders the patient unsuitable for the trial according to the investigator's judgment

Where

7 study sites

FacilityCityRegionCountry
Investigational SiteDresdenGermany
Investigational SiteFrankfurtGermany
Investigational SiteMünsterGermany
Investigational SiteLeidenNetherlands
Investigational SiteMaastrichtNetherlands
Investigational SiteLondonUnited Kingdom
Investigation SiteOxfordUnited Kingdom

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT05839509 on ClinicalTrials.gov →

Last updated in the registry 2025-02-18. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits